Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 2nd, 2026

LECO_Weekly-Healthcare-News_2-2-2026Download
  1. Boston Scientific (NYSE: BSX) completes $600M acquisition of Nalu Medical to deepen neuromodulation portfolio for chronic pain The deal adds Nalu’s miniaturized, battery‑free implantable pulse generator for spinal cord and peripheral nerve stimulation, wirelessly powered by an external wearable disc and controlled via smartphone, with an expected 18‑year service life. Nalu’s system, cleared initially by the FDA in 2019 and later for whole‑body MRI use, delivers neuromodulation for chronic neuropathic pain with capabilities comparable to larger IPGs. Boston Scientific projects Nalu revenue above $60 million in 2025 with more than 25% growth in 2026 and expects the transaction to become increasingly accretive to earnings after 2027. (Link)
  2. Laborie acquires JADA System for $465M, backed by Patricia Industries to strengthen its global maternal health and postpartum haemorrhage care portfolio The acquisition brings an FDA-cleared device for rapid control of abnormal postpartum uterine bleeding into Laborie’s comprehensive obstetrics portfolio spanning antepartum through neonatal care. JADA uses low-level vacuum to stimulate natural uterine contractions, helping stop postpartum haemorrhage quickly and effectively and has already been used in more than 136,000 mothers across over 20 countries, supported by multiple safety and effectiveness studies. Laborie will onboard over 90 primarily commercial team members as part of a long-term strategy to back innovations that improve maternal outcomes and support sustainable growth. (Link)
  3. Halozyme Therapeutics acquires Surf Bio for up to $400M to expand hyperconcentration capabilities in subcutaneous drug delivery The transaction, closed in late December 2025 and announced January 28, 2026, includes $300M upfront (subject to adjustments) and up to $100M in development/regulatory milestones. Surf Bio’s platform enables high-concentration formulation of monoclonal antibodies, small molecules, and biologics using spray drying, a novel protective excipient, and polymer-based surface tension reduction for protein stability and low-friction delivery via auto-injector. Complementing Halozyme’s Enhanze hyaluronidase and recent Elektrofi/Hypercon acquisition, the technology extends IP into the mid-2040s, opens non-exclusive partnerships across autoimmune, neurology, nephrology, cardiovascular, nucleic acids, and ADCs, and supports rapid home-administration innovations, positioning Halozyme for durable royalty growth and next-generation delivery leadership. (Link)
  4. Illumina (NASD: LMN) acquires SomaLogic and assets from Standard BioTools for $350 million plus milestones to expand proteomics and multiomics leadership The acquisition strengthens Illumina’s position in the fast-growing proteomics market by integrating SomaLogic’s data-driven protein analysis technologies with Illumina’s next-generation sequencing (NGS) and multiomics solutions. Customers will gain access to enhanced tools, including SomaScan assays, DRAGEN software, and Illumina Connected Multiomics, enabling large-scale, flexible, and cost-efficient analysis of complex biological data. The combination supports faster drug discovery and deeper insights into human health. Illumina will maintain continuity for existing SomaLogic customers while expanding global access to the unified platform, investing in scalable growth and innovation across its sequencing and proteomics ecosystems. (Link)
  5. Sword Health acquires Kaia Health in $285M transaction backed by General Catalyst, Khosla Ventures, Transformation Capital and Founders Fund to scale AI-first MSK and pulmonary care in the U.S. and Germany The transaction adds Kaia’s digital musculoskeletal and pulmonary programs and its coveted position in Germany’s reimbursed digital health pathway, giving access to more than 70 million publicly insured individuals. Sword plans to migrate Kaia’s U.S. members to its own AI Care platform, unifying client relationships while extending a wider range of AI-enabled remote services that blend automation with clinician oversight. The combined organization aims use of AI care manager agents to automate administrative tasks and support more accessible virtual care. (Link)
  6. Premise Health acquires Crossover Health, via its financial sponsors OMERS Private Equity, Ares Management, and Ares Capital Corporation BDC creating unified advanced primary and occupational care company The combined organization will operate nearly 900 onsite, nearsite and virtual wellness centers, serving more than 400 employers, unions, tribes and health plans across the U.S. Its integrated model spans advanced primary care, occupational health, behavioral health, care management and navigation, physical therapy and chiropractic, with Premise’s pharmacy services adding chronic condition support and virtual dispensing. Both companies will continue developing alternative payment models, including a primary‑care‑centered health plan, with leadership from both executive teams retained to drive a shared vision of scalable, team‑based primary care that lowers costs and improves outcomes. (Link)
  7. Spring Health to acquire Alma in deal backed by Generation Investment Management, Tiger Global, Thoma Bravo, Cigna Ventures, Optum Ventures, Insight Partners, Tusk Venture Partners, Primary Venture Partners, and Sound Ventures to build AI-enabled lifelong mental health platform and expand nationwide care access The acquisition unites two major digital mental health innovators, combining Spring Health’s AI-driven precision care platform with Alma’s strong national payer relationships and provider infrastructure. The deal will integrate advanced technology, data-informed personalization, and in-network clinician enablement to improve patient outcomes while easing administrative burdens. Both leverage shared resources to advance quality, accessibility, and value across the evolving mental healthcare ecosystem. (Link)
  8. Resonetics to acquire Resolution Medical in a Carlyle, GTCR and Arcline Investment Management–backed deal to expand neuromodulation and structural heart device capabilities The acquisition will add Resolution Medical’s integrated design, engineering and cleanroom manufacturing capabilities for complex Class II and III devices, significantly deepening Resonetics’ presence in neuromodulation, structural heart and interventional cardiology markets. More than 240 employees, including over 100 engineers, will join Resonetics, enabling it to support customers from early product design and NPI through high‑volume production on a larger global footprint. Both organizations emphasize continuity for existing customers while positioning the combined company as a more comprehensive development and manufacturing partner across the full medical device lifecycle. (Link)
  9. Kodiak Solutions acquires BESLER, via its financial sponsor TPG to strengthen revenue recovery and reimbursement capabilities The acquisition brings BESLER’s revenue integrity tools, including Transfer DRG underpayment detection software and managed reimbursement services, onto Kodiak’s existing analytics and automation platform for hospitals and medical practices. Kodiak aims to give health system CFOs deeper, more actionable insight into net revenue, benchmarking, and reimbursement performance while simplifying complex business office workflows. BESLER’s leadership and subject-matter experts, including former CEO Jonathan Besler, are joining Kodiak to help support more than 2,300 hospitals and 350,000 physicians, while founder Philip Besler retires after four decades building the firm. (Link)
  10. Nuwellis (NASD: NUWE) to acquire Rendiatech to expand real-time kidney function monitoring and advance cardiorenal care portfolio The acquisition advances Nuwellis’ move beyond fluid management into continuous renal diagnostics, enhancing its precision cardiorenal care capabilities. Rendiatech’s Clarity™ system provides automated, continuous urine-output monitoring, offering improved accuracy and efficiency over manual methods. The integration of this technology will support earlier kidney stress detection and data-driven clinical decisions in critical care. Nuwellis plans to use its existing commercial and clinical infrastructure to bring Rendiatech’s innovation to market without new sales channels. The transaction, approved by both companies’ boards, marks a key milestone in establishing a more comprehensive cardiorenal platform once customary closing conditions are met. (Link)
  11. Wisp acquires TBD Health to build women-focused national PrEP and sexual health enterprise and hybrid care platform The deal adds a 50‑state sexual health and diagnostics infrastructure, including routine STI/HIV testing, virtual clinical support and deep partnerships with hospital systems and public health organizations. TBD Health’s TelePrEP and diagnostics capabilities, already integrated with partners like Mount Sinai Health System, San Francisco AIDS Foundation and Planned Parenthood Direct, will underpin Wisp’s move beyond direct‑to‑consumer into enterprise and hybrid care models. Together, the companies plan to close major gaps in preventive sexual health—particularly for women—by offering turnkey PrEP and testing solutions that plug into existing clinical workflows and broaden access across consumer, employer and public health channels. (Link)
  12. NOCD acquires Rebound Health, leveraging Noto AI platform to scale virtual OCD and PTSD specialty care The combined organization will expand virtual, evidence-based therapy for OCD and trauma-related disorders nationwide using Noto, an AI-powered infrastructure that supports payer operations, member identification, enrolment, and clinical workflows. NOCD contributes a large, W‑2-employed therapist network delivering more than 1 million OCD sessions annually, supported by tools like AI-assisted notetaking, outcomes tracking, and peer support between visits. Clinical studies of NOCD’s virtual exposure and response prevention model show meaningful symptom reductions for children and teens, while peer interventions increase engagement, and Noto will now also be used to scale Rebound’s PTSD and complex PTSD services across the U.S. (Link)
  13. Premier Radiology Services to acquire National Radiology Solutions (NRAD) to strengthen nationwide teleradiology network and clinical coverage The merger combines two established teleradiology providers to create a stronger national network with enhanced clinical coverage and streamlined operations. By integrating technological infrastructure, administrative systems, and subspecialty expertise, the unified organization will deliver faster, more accurate diagnostic interpretations. NRAD’s team, including founder Robb Kolb, will join the combined company to ensure seamless service for existing clients. The partnership places emphasis on physician autonomy, innovation, and expanding access to high-quality radiology services. Together, the organizations aim to advance patient care standards and improve efficiency for outpatient healthcare providers across the United States. (Link)
  14. Choice Health at Home to acquire Cy-Fair Health Care and Alliant, via its financial sponsor Trive Capital to expand home health and hospice services across key Southwestern markets The acquisition builds on Choice Health at Home’s strategy to enhance integrated home-based care across key Southwestern markets. Both Cy-Fair Health Care in Texas and Alliant in Colorado bring strong clinical reputations and deep community roots, which will now be supported by Choice Health’s broader operational infrastructure and resources. The move strengthens continuity of care for patients and families, with existing staff retained and services uninterrupted. By combining expertise, technology, and compassionate clinical teams, the expanded organization will improve home health and hospice delivery while advancing Choice Health’s mission to provide accessible, patient-centered care across its seven-state network. (Link)
  15. ncgCARE to acquire Broadstep of North Carolina through Carolina Outreach to expand statewide behavioral health services The acquisition broadens ncgCARE’s community-based behavioral health network across eastern and southeastern North Carolina, reinforcing its commitment to accessible, high-quality mental health and substance use care. Broadstep’s existing staff, leadership, and programs will remain in place, ensuring continuity for patients and families. By integrating Broadstep’s operations into Carolina Outreach, ncgCARE will provide expanded operational, clinical, and compliance support to strengthen long-term sustainability and service delivery. The partnership emphasizes stability, quality, and local engagement while enhancing capacity to meet growing behavioral health needs in communities across Gastonia, Lumberton, Jacksonville, Supply, and Wilmington, North Carolina. (Link)

Venture and Other News  

  1. Vaxcyte prices $550M public offering at $50 per share to fund pneumococcal and infectious disease vaccine pipeline The offering includes 11,000,000 shares with a 30-day underwriter option for up to 1,650,000 additional shares, expecting gross proceeds of $550M (before discounts/expenses), closing February 2, 2026. Proceeds will support clinical advancement of lead next-generation pneumococcal conjugate vaccine VAX-31 (Phase 3 adult/Phase 2 infant), VAX-24, plus prophylactic programs for Group A Strep (VAX-A1) and Shigella (VAX-GI). Leveraging its XpressCF cell-free protein synthesis platform for high-fidelity conjugates, Vaxcyte aims to address serious bacterial diseases with broader, more effective immunizations, accelerating late-stage trials, manufacturing scale-up, and progress toward preventing unmet infectious threats. (Link)
  2. Veradermics and Eikon Therapeutics file for IPOs targeting up to $181M and $318M amid biotech market reopening Veradermics (NYSE: MANE) seeks approximately $181M to advance Phase III VDPHL01 (extended-release oral minoxidil) for pattern hair loss in men and women, supporting approval, commercialization, physician education, brand awareness, supply chain, and infrastructure in dermatology. Eikon Therapeutics (Nasdaq: EIKN), led by former Merck executive Roger Perlmutter, targets up to $318M (with overallotment) primarily for clinical progression of TLR7/8 agonists EIK1001 (melanoma) and EIK1003 (non-small cell lung cancer), plus selective PARP1 inhibitors and WRN helicase assets in challenging oncology indications. The January 2026 filings signal renewed investor confidence post-2025 slowdown, enabling late-stage advancement, pipeline expansion, and public-market capitalization for these high-potential biotechs. (Link)
  3. Cellares raises $257M in Series D round led by Eclipse and BlackRock with participation from T. Rowe Price, Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures and DFJ Growth to scale global cell therapy manufacturing The new funding supports Cellares’ global expansion as it prepares for commercial-scale cell therapy production by 2027. The company will build new manufacturing facilities in the Netherlands and Japan, complementing sites in New Jersey and South San Francisco. Its automated “Cell Shuttle” system enables end-to-end cell therapy production, addressing industry bottlenecks through scalable, high-tech infrastructure. With increasing demand and regulatory validation, Cellares is positioning itself as a leading integrated developer and manufacturer supporting global biopharma partners, including Bristol Myers Squibb. The financing advances its mission to industrialize cell therapy and move toward a public listing. (Link)
  4. Tenpoint Therapeutics raises $235M from Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille, and Hercules Capital to accelerate commercialization of YUVEZZI™ The financing strengthens Tenpoint Therapeutics’ position for the commercial launch of YUVEZZI™, the first FDA-approved dual-agent, once-daily eye drop for presbyopia. The funding includes an $85 million Series B round and a $150 million credit facility, providing the capital needed to scale manufacturing, distribution, and marketing. Tenpoint aims to meet the needs of millions affected by age-related vision decline while delivering a differentiated treatment backed by strong clinical data and safety performance. The company’s leadership is focused on driving YUVEZZI™’s successful rollout and expanding access to innovative ophthalmic solutions. (Link)
  5. Breakthru Medicine emerges from stealth with $60M Series A financing to advance disruptive cancer therapeutics The funding, supported by investors including Dave Morehead (Baylor University endowment), Fred Eshelman (Eshelman Ventures), and Mark Gergen, enables Breakthru Medicine to build its tumor-agnostic platform targeting hard-to-drug cancers through small molecules, next-generation antibody-drug conjugate payloads, and a novel molecular glue approach. The company prioritizes patient-first development by rigorously selecting breakthrough candidates early and eliminating non-viable programs. The capital accelerates pipeline progression and platform expansion to redefine therapeutic possibilities for oncology indications. (Link)
  6. TRexBio raises $50M from Janus Henderson Investors, Alexandria Venture Investments, Avego BioScience Capital, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and SV Health Investors to advance tissue-targeted Treg immunology pipeline The financing supports TRexBio’s ongoing clinical and preclinical programs focused on tissue-specific regulatory T cell therapies for autoimmune and inflammatory diseases.. Leveraging its Deep Biology Platform, TRexBio maps tissue Treg behavior to uncover novel therapeutic targets. The investment underscores confidence in the company’s precision immunoregulatory approach aimed at delivering more effective, durable treatments for diseases such as atopic dermatitis and other inflammatory disorders. (Link)
  7. Prenosis secures $20M Series A led by PACE Healthcare Capital with UC Investments, UCI Health Ventures, Labcorp Venture Fund, GHIC, Illinois DCEO, and Carle Health, plus $20M BARDA contract to advance AI diagnostics and therapeutics The combined $40 million will drive Prenosis’ development of biology-based, AI-powered diagnostic and therapeutic tools for critical care conditions such as sepsis, ARDS, and acute kidney injury. The BARDA-funded program will include a pivotal clinical trial evaluating an AI-enabled steroid companion diagnostic for severe respiratory infections. These initiatives strengthen Prenosis’ mission to personalize treatment by combining advanced diagnostics with targeted therapeutics, marking a major step in improving outcomes for critically ill patients through precision care. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jan 20th, 2026

LECO_Weekly-Healthcare-News_1-20-2026-1Download

Healthcare Weekly News and Deals – January 20th, 2026

  1. Takeaways from JPM 44th Annual Healthcare Conference 2026 The J.P. Morgan Healthcare Conference 2026 reflected a turn toward cautious yet genuineoptimism, fueled by policy tailwinds, AI’s proven impacts, and robust activity in strategiccollaborations and consolidations. AI emerged as a core driver, transitioning from hype tooperational ROI via agentic systems, closed-loop workflows, and ambient tools that enhancediscovery, delivery, and administrative efficiency. Federal efforts, including outreach on quality andaccess alongside high-impact innovation programs, underscore a proactive stance on reducingbarriers and accelerating progress. Cross-border dynamics and emerging modalities added to theforward-looking tone, signaling diversified growth opportunities. The event highlightedhealthcare’s trajectory for AI-enabled reinvention, with widespread alignment on prioritizingefficiency, transparency, execution, and adaptive strategies to navigate global and regulatory shifts.
    ● PitchBook Analyst Note: Takeaways from the J.P. Morgan Healthcare Conference (Link)
  2. OpenAI acquires Torch in ~$100M deal to accelerate ChatGPT Health OpenAI bought healthcare startup Torch, which aggregates users’ lab results, medications, visit notes, wearable data and consumer test reports into a unified health record, and will fold its team into efforts to expand ChatGPT Health. The year‑old Torch platform was built as a “medical memory” to unify fragmented records into a single context layer for AI. The acquisition follows OpenAI’s launch of ChatGPT Health, which links the chatbot to medical records and wellness apps for more personalized responses. OpenAI reports that about one in four of ChatGPT’s 800 million regular users asks at least one healthcare‑related question each week. (Link)
  3. Boston Scientific (NYSE: BSX) to acquire Penumbra (NYSE: PEN) in $14.5B cash-and-stock deal to expand vascular and neurovascular portfolio The transaction will be paid approximately 73% in cash and 27% in Boston Scientific stock, giving Penumbra shareholders the option of cash or shares subject to proration. Penumbra brings a portfolio that includes Lightning Bolt and Lightning Flash computer-assisted vacuum thrombectomy systems, peripheral embolization solutions, and neurovascular devices for stroke, aneurysms and other complex vascular conditions. Boston Scientific plans to fund the roughly $11 billion cash component with a mix of cash on hand and new debt and currently expects the deal to be modestly dilutive to adjusted earnings per share in the first full year after closing, turning neutral to accretive thereafter. (Link)
  4. Smith+Nephew (NYSE: SNN) to acquire Integrity Orthopaedics in Deal Worth up to $450M to Strengthen Rotator Cuff Portfolio The transaction includes an upfront $225 million cash payment plus up to $225 million in performance-based milestones over five years and is expected to close this month. Integrity Orthopaedics’ Tendon Seam rotator cuff repair system is designed with patented micro-anchors, individually locked stitches and an integrated implantation system to reduce re-tear rates and shorten procedures compared with traditional techniques, which can have structural failure rates of 20–40%. The acquisition supports Smith+Nephew’s RISE 2026 strategy and builds on prior shoulder investments, including the Regeneten bioinductive implant, Q-Fix Knotless All-Suture Anchor and the Aetos Shoulder System. (Link)
  5. Modella AI acquired by AstraZeneca (LON: AZN) to scale AI-driven oncology R&D globally The acquisition expands a multi-year collaboration by embedding Modella AI’s multimodal foundation models and agentic AI platform directly into AstraZeneca’s oncology research and development ecosystem. Modella AI’s technology, built at the intersection of pathology, clinical data and advanced generative AI, will be used to accelerate clinical development, enhance biomarker discovery and support data‑driven decision-making across AstraZeneca’s global oncology portfolio. AstraZeneca plans to deploy these AI agents and pathology foundation models to increase automation, scalability and consistency in data‑intensive workflows and to support the development of targeted therapeutics and companion diagnostics. (Link)
  6. Boston Scientific (NYSE: BSX) acquires Valencia Technologies to add eCoin ITNS device to urology portfolio The eCoin implantable tibial nerve stimulation system, placed under the skin near the ankle, is intended for urge urinary incontinence patients who do not tolerate or sufficiently benefit from conservative therapies, and received FDA clearance in 2022. In a pivotal study, 68% of treated patients achieved at least a 50% reduction in UUI episodes, underscoring its potential clinical impact. The transaction is expected to close in the first half of 2026, positioning Boston Scientific alongside Medtronic’s Altaviva device in the growing neuromodulation market for overactive bladder–related symptoms as the company continues to expand its pelvic health and neurology device franchises. (Link)
  7. Abbott (NYSE: ABT) and AtaCor collaborate on Next-Generation Extravascular ICD System The partners are combining an investigational parasternal extravascular defibrillation lead (Atala) with a minimally invasive implantable defibrillator platform intended to keep hardware outside the heart and vasculature, aiming to avoid complications such as vascular injury, lead fracture and infections. The Atala lead is placed through a rib space beside the sternum and is designed both to deliver defibrillation shocks and to direct pacing energy efficiently toward the heart. A pivotal ALARION EV Investigational Device Exemption study is planned for 2026 to evaluate the system as a potential new option for patients at high risk of life‑threatening arrhythmias. (Link)
  8. Hippocratic AI acquires Grove AI to build end-to-end agentic AI platform for biopharma and medtech The acquisition adds Grove AI’s agentic platform, which has supported over 10 million patient interactions and powered more than 50 phase 2 and 3 clinical trials, into Hippocratic AI’s life sciences division focused on regulated biopharma and MedTech use cases. Grove’s “Grace” agent and participant relationship management tools will be used to speed recruitment, improve screening and streamline trial operations across top global pharma partners, while Hippocratic extends agents into commercial, direct‑to‑patient and HCP engagement. The company has appointed Ahad Wahid, M.D., as president of life sciences and formed a senior advisory council to ensure safety, compliance and large‑scale deployment. (Link)
  9. Agentis Longevity acquires Arete Wellness, via its financial sponsor Shore Capital Partners to build national precision longevity and recovery platform The combined company will offer personalized, preventative programs that integrate advanced diagnostics, hormone and peptide therapies, IV recovery, performance medicine and lifestyle-focused support for high-performing clients such as professional athletes, entertainers and executives. Arete contributes a concierge recovery model delivered by a team of more than 45 traveling nurses and medical professionals, while Agentis brings precision-based longevity medicine focused on individualized, science-backed care. Leadership from both organizations position the deal as a way to expand geographic reach, increase accessibility and set a new standard for evidence-based performance longevity without disclosing financial terms. (Link)
  10. Apollo Care acquires eStrat, via its financial sponsor Flexpoint Ford to expand copay and patient access capabilities Apollo Care is adding eStrat’s copay program design and execution expertise to strengthen its technology-driven patient access, affordability and analytics platform. The combined offering aims to enable faster copay program launches, tighter integration between operations and analytics, and more seamless execution for pharmaceutical manufacturers across multiple therapeutic areas. Key eStrat team members are joining Apollo Care to ensure continuity for existing clients, with co-founder Trond Waerness stepping into a leadership role focused on patient affordability strategy. The companies say the deal will help manufacturers reduce complexity while improving access and affordability for patients. (Link)
  11. Zelis acquires Rivet, via its financial sponsors Bain Capital, Parthenon Capital Partners, Valspring Capital, BPEA Private Equity, Edison Partners, Bain Capital Ventures, Norwest, Ergo Partners, HarbourVest Partners and Mubadala Investment Company, to expand AI‑enabled revenue cycle analytics for healthcare payers and providers The deal adds Rivet’s analytics platform to Zelis’ existing payments technology, giving providers deeper visibility into claim payment patterns and denial trends via insight‑rich dashboards and workflow tools. By reducing transactional back‑and‑forth, payers can shift focus to collaborative efforts that improve first‑time claim success and cut down on costly rework. Executives from both companies frame the combination as a way to address mounting margin pressure, rising administrative costs and regulatory complexity while pushing the industry toward a more transparent, efficient financial experience for providers, payers and patients. (Link)
  12. Genomate Health acquires Oncompass Medicine to build integrated precision oncology platform in Europe The deal gives Genomate Health a long-standing European base with established logistics, clinical operations and market presence in personalized oncology, particularly in Hungary and across Europe. Oncompass, founded in 2003, brings two decades of experience in companion diagnostics and next-generation sequencing-based tumour profiling in routine clinical care. Scientific and clinical leadership will be driven by Genomate Health Founder and CSO Istvan Petak, who will also serve as Managing Director of Oncompass Medicine, as the combined organization deploys Genomate’s computational reasoning technology to turn complex molecular data into scalable, actionable treatment decisions for cancer patients worldwide. (Link)
  13. Behavioral Framework partners with Autism ETC, backed by Renovus Capital Partners, to expand autism care platform Autism ETC, which operates five ABA therapy and autism diagnostic clinics in Tennessee and Arizona, will join Behavioral Framework while retaining its leadership team and clinical staff to ensure continuity for families and employees. The combination is intended to extend high-quality, individualized autism services across both center-based and home-based models in the Southeast and beyond, supported by Behavioral Framework’s operational infrastructure, technology and growth resources. Both organizations emphasize preserving Autism ETC’s culture and clinical integrity while scaling access and investing in clinician development as part of Behavioral Framework’s broader growth strategy. (Link)
  14. EnableComp acquires Health Resources Optimization via its financial sponsors Primus Capital and Welsh, Carson, Anderson & Stowe to expand complex revenue recovery for hospitals The acquisition brings H/ROI’s clinical denials and post‑bill DRG validation expertise under EnableComp, strengthening its focus on complex claims, DRG downgrades and medical‑necessity denials. The combined organization aims to capture more hidden revenue for providers facing intense margin pressure and payer scrutiny by pairing seasoned clinical judgment with an AI‑driven revenue cycle platform. Serving over 1,000 hospitals and recovering $3 billion annually, EnableComp is integrating H/ROI to deliver deeper clinical insights, earlier underpayment detection and faster resolution of intricate denials so health systems can safeguard margins and improve financial stability while maintaining patient care. (Link)
  15. Solis Mammography acquires Women’s Center for Radiology, via its financial sponsors Madison Dearborn Partners and TowerBrook Capital Partners to expand Florida breast imaging footprint The deal adds two Orlando centers to Solis Mammography’s existing nine Florida locations in Gainesville, Fort Lauderdale and Miami, marking the company’s entry into the Orlando market and broadening its statewide presence in specialized breast health services. The combined organization aims to deliver comfortable, convenient and compassionate breast imaging to more patients across greater Florida while maintaining personalized, community-focused care. (Link)

Venture and Other News   

  1. JPM26: Anthropic launches Claude for Healthcare to Turbocharge AI efficiency at HealthSystems, Payers Anthropic introduced Claude for Healthcare at the J.P. Morgan Healthcare Conference (JPM26), providing purpose-built, HIPAA-ready AI tools for health systems, payers, providers, and hospitals to accelerate administrative and clinical workflows including prior authorization, clinical documentation, claims management, care coordination, regulatory submissions, and patient message triage. The platform connects Claude to key data sources such as the CMS Coverage Database (Local and National Coverage Determinations), ICD-10 codes, National Provider Identifier Registry, and PubMed (with over 35 million biomedical literature entries), enabling natural language querying, surfacing coverage differences, reducing claim denials, and supporting FHIR interoperability via Agent Skills. It builds on the October launch of Claude for Life Sciences with additional connectors for platforms like Medidata and ClinicalTrials.gov, while offering consumer-facing features like medical history summarization and health metric pattern detection through beta integrations with HealthEx, Function, Apple Health, and Android Health Connect. Emphasizing AI safety through its Constitutional AI approach, the tools aim to minimize hallucinations, ensure reproducible and cited results, and amplify human capabilities in highstakes, regulated healthcare environments, with early adoption by organizations including Banner Health, Stanford Healthcare, Novo Nordisk, Sanofi, AbbVie, and Genmab. (Link)
  2. OpenAI Invests in Merge Labs’ $250M Seed Led by OpenAI with Bain Capital, Interface Fund, Fifty Years and Gabe Newell to Advance Noninvasive Brain‑Computer Interfaces Merge Labs, a brain-computer interface “research lab” co-founded by Sam Altman and collaborators from Tools for Humanity, Forest Neurotech and Caltech, raised $250 million at an $850 million valuation to pursue non-invasive BCIs that link biological and artificial intelligence using molecules and deep-reaching modalities like ultrasound. The startup aims to extend human capabilities and restore or enhance brain function by interfacing with neurons at scale, with applications well beyond current medical BCI use cases. OpenAI plans to collaborate with Merge on foundation models and AI operating systems that interpret neural intent and work robustly with limited, noisy brain signals. (Link)
  3. Proxima raises $80M Seed Led by DCVC with NVentures, Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments and Modi Ventures to Advance Proximity-Based Medicines The AI-native biotech, formerly VantAI, is developing proximity therapeutics that modulate protein–protein interactions, including modalities like molecular glues and PROTACs, to reach historically “undruggable” targets across oncology, immunology and other diseases. Its NeoLink data-generation technology and Neo AI model series generate proteome-scale structural data on protein complexes to enable rational design of proximity-modulating small molecules, with aims to improve safety and shorten development timelines. The company has secured multibillion-dollar research collaborations with Johnson & Johnson, Bristol Myers Squibb and Blueprint Medicines, with multiple partnered programs progressing toward the clinic and the first expected to enter trials in 2026. (Link)
  4. Vista AI raises $29.5M series B with Cedars-Sinai Health System, Intermountain Health, University of Utah Hospital System, Temple University/Fox Chase Cancer Center, Tampa General Hospital, Khosla Ventures and Bold Brain Capital to Expand Automated MRI Imaging Platform The company’s AI software automates MRI scanning workflows to reduce complexity and variability, helping radiology teams keep up with rising MRI demand amid technologist shortages. Vista AI plans to expand from its FDA-cleared cardiac MRI platform into brain, prostate and spine imaging and add remote scanning services so sites without in-house expertise can offer advanced exams. Early adopters such as Brigham and Women’s Hospital and Radiology Regional report 50% more cardiac MRI slots, elimination of a 28-day backlog, and scan times cut by more than half without adding staff or scanners. (Link)
  5. Converge Bio raises $25M Series A Led by Bessemer Venture Partners with TLV Partners, Saras Capital, Vintage Investment Partners and Executives from Meta, OpenAI and Wiz to Accelerate AI-Driven Drug Discovery The Boston- and Tel Aviv-based startup builds generative AI models trained on DNA, RNA and protein sequences to plug directly into pharma and biotech workflows across target discovery, antibody design, protein yield optimization and biomarker discovery. Its customer-facing systems integrate generative, predictive and physics-based docking models so clients receive ready-to-use platforms rather than stitching tools together. In two years, Converge has completed more than 40 programs with over a dozen customers across the U.S., Canada, Europe and Israel, reporting up to 4–4.5X protein yield gains and single‑nanomolar affinity antibodies, and is now expanding into Asia. (Link)
Neil Johnson No Comments

News Healthcare Deals, Investments & Update Week ending Nov 10th 2025

LECO_Weekly-Healthcare-News_11-10-2025Download

    1. BillionToOne (NASD: BLLN) raises $273 Million in U.S. IPO Led by J.P. Morgan, Piper Sandler, Jefferies, and William Blair

    The firm’s technology powers advanced prenatal and oncology diagnostics through its Unity and Northstar tests. Analysts view its IPO success as reflecting growing investor confidence in biotech innovation despite wider market uncertainty. The offering signals renewed momentum in healthcare listings, inspired by other major sector filings such as Medline’s. (Link)

    2. Sonida Senior Living (NYSE: SNDA) and CNL Healthcare Properties announce $1.8 Billion Merger Creating the Nation’s Eighth Largest Senior Housing Owner

    The merger focuses on expanding nationwide senior living operations with an emphasis on quality care and operational integrity. Both companies aim to strengthen their market position through shared values and strategic growth in key U.S. regions, while investors anticipate improved financial performance and stronger long-term value within the senior housing sector. (Link)

    3. QOL Medical to acquire Evoke Pharma (NYSE: EVOK) in All-Cash Deal Worth $11 Per Share

    The agreement merges complementary strengths in gastrointestinal innovation, expanding access to advanced treatments for diabetic gastroparesis. Both companies underscored the transaction’s strategic value in broadening therapeutic offerings and commercial reach. Supported by cash reserves, the acquisition awaits regulatory and shareholder approval, marking a step toward enhanced capabilities in GI-focused patient care. (Link)

    4. Organon sells Jada System to Laborie Medical Technologies in $465 Million Deal

    The transaction supports reorganization and debt reduction, positioning both companies for strategic growth. Laborie will expand its maternal health portfolio by incorporating the Jada device and its specialized workforce. Organon aims to redirect focus toward women’s health biopharma opportunities after recent leadership transitions, declining sales, and halted drug development initiatives. (Link)

    5. Lifecare Home Health acquires Infinity Hospice Care, via its financial sponsor Zenyth Partners, expands Hospice Services Across Nevada and Arizona

    The collaboration enhances post-acute care delivery through unified expertise in compassionate and high-acuity hospice services. Combining national infrastructure with community-based operations, both organizations aim to elevate patient experiences centered on dignity and care quality. Leadership underscores innovation and continuity as key drivers in expanding coordinated healthcare across multiple states. (Link)

    6. Optain Health acquires EyePACS to Advance AI-Driven Retinal Screening and Oculomics Innovation

    The collaboration enhances early disease detection through advanced AI imaging, expanding access to preventive care and population health programs. EyePACS’s nationwide network will integrate Optain’s automation and multilingual capabilities, improving clinical efficiency and diagnostic scalability while advancing oculomics research aimed at identifying systemic diseases through non-invasive retinal analysis. (Link)

    7. JLL Partners combines Vascular Technology Incorporated and Parks Medical Electronics to Build Vascular and Robotics Device Platform

    The merger unites advanced capabilities in vascular diagnostics and Doppler ultrasound technologies to enhance precision and clinical performance. By combining innovation with U.S.-based production, the partnership focuses on improving device reliability and expanding access to next-generation vascular tools that support surgical, therapeutic, and diagnostic applications worldwide. (Link)

    8. Omega Systems acquires PEAKE Technology Partners, via its financial sponsor Revelstoke Capital Partners to strengthen Healthcare Managed IT and Cybersecurity Capabilities

    The acquisition enhances healthcare IT services through advanced data security, compliance, and AI-driven clinical capabilities. By integrating expertise in electronic health records and HIPAA management, the partnership aims to boost operational performance and patient outcomes while expanding regional reach and reinforcing leadership in secure, technology-driven healthcare infrastructure nationwide. (Link)

    9. Acumed acquires TECHFIT Digital Surgery Assets to Advance Patient-Tailored Craniomaxillofacial Solutions

    The integration brings advanced digital planning and reconstruction capabilities to improve precision in surgical procedures across multiple specialties. By expanding personalized, data-driven care, the company aims to advance innovation in reconstructive and orthopaedic solutions. Leadership additions and global strategy alignment will support broader adoption of patient-tailored surgical technologies worldwide. (Link)

    10. RadNet and DeepHealth acquire Alpha RT to Expand Remote MRI Scanning and AI Safety Capabilities

    The integration enhances imaging efficiency through AI-powered monitoring, advanced training, and resource optimization to tackle technologist shortages. By combining intelligent staffing with remote imaging technology, the partnership strengthens scalability and nationwide support. It aligns with continued investments in AI-driven diagnostics, expanding capabilities across multiple medical imaging modalities and platforms. (Link)

    Neil Johnson No Comments

    News Healthcare Deals, Investments & Update Week ending Oct 27th 2025

    LECO_Weekly-Healthcare-News_10-27-2025Download

      1. Hologic (NASD: HOLX) to go private in $18.3 Billion acquisition by Blackstone and TPG, Minority Stakes for Abu Dhabi Investment Authority and GIC     The transaction is designed to deliver compelling value to shareholders and highlights continued innovation in women’s health and AI-driven diagnostics. Hologic will maintain its brand and headquarters while operating privately. The agreement includes a 45-day “go-shop” period, and closing remains subject to regulatory and shareholder approvals, with completion anticipated in the first half of 2026. (Link)

      2. Novartis (NYSE: NVS) to acquire Avidity Biosciences (NASD: RNA) for $12 Billion; SpinCo to Emerge as Independent Cardiology-Focused Company The deal, unanimously approved by both boards, will give Novartis global rights to innovative RNA-based neuromuscular therapies and boost its neuroscience pipeline with potential first-in-class candidates. Avidity shareholders will receive additional SpinCo stock or cash linked to its cardiology assets. Regulatory and shareholder approvals are pending. (Link)

      3. Eli Lilly (NYSE: LLY) to acquire Adverum Biotechnologies (NASD: ADVM) in Deal Centered on Ixo-vec Gene Therapy Lilly’s purchase will help advance Ixo-vec, a novel gene therapy for vision loss, offering shareholders potential milestone payments based on regulatory and sales goals. This late-stage treatment addresses a major unmet need for wet age-related macular degeneration. The acquisition also secures short-term funding for Adverum’s clinical progress. (Link)

      4. Alkermes (NASD: ALKS) to acquire Avadel Pharmaceuticals (NASD: AVDL) for Up to $2.1 Billion, Expanding Sleep Medicine Portfolio with LUMRYZ™ Alkermes’ acquisition adds the FDA-approved LUMRYZ™, a once-at-bedtime sodium oxybate treatment for narcolepsy symptoms like cataplexy and excessive daytime sleepiness. The deal offers shareholders $18.50 upfront plus $1.50 contingent on FDA label expansion, a 38% premium over recent prices. Closing is expected in Q1 2026, enhancing Alkermes’ sleep medicine portfolio and leveraging Avadel’s expertise for future pipeline development. (Link)

      5. DocGo (NASD: DCGO) acquires SteadyMD to Expand Telehealth Services Nationwide; SteadyMD Co-Founders Join Leadership Team DocGo acquired SteadyMD to expand its telehealth reach across all 50 states, integrating SteadyMD’s virtual clinician network with its mobile healthcare services. SteadyMD, expected to generate $25 million in 2025, serves over 3 million patients, including Fortune 10 clients. SteadyMD’s leadership joins DocGo’s team, and the acquisition is funded by DocGo’s cash reserves. (Link)

      6. Lemonaid Health acquired by Bambu Ventures to relaunch as Independent Telemedicine Platform after Bankruptcy Lemonaid Health, after bankruptcy will pursue aggressive growth as an independent telemedicine and pharmacy platform. Bambu and Innova Partners provide executive leadership, focusing on affordable care, same-day prescriptions, and market expansion. Key board appointments and new investors support innovation and differentiation. (Link)

        7. Opyn Health, Inc. acquires Empara to Integrate AI-Driven Benefits Engagement and Boost Platform for Self-Insured Healthcare Combining Opyn’s price transparency and virtual care expertise with Empara’s AI-powered app streamlines benefits administration and cost management for members and administrators. Empara’s founders join Opyn, and the unified platform will serve TPAs, brokers, and self-insured employers—aiming to replace legacy systems with a seamless digital access point for healthcare. (Link)

        8. Oasis Health Partners® acquires PreferCare to Strengthen Value-Based, Preventive Primary Care for Seniors in North Carolina PreferCare enhances Oasis’s capabilities with in-home and virtual care for seniors, leveraging new tools, analytics, and clinical support. The partnership improves coordinated care, preventive screenings, and early interventions. By empowering physicians and supporting practices, Oasis advances health equity and outcomes, building healthier communities through a value-based care model. (Link)

        9. Duly Health and Care acquire Woodridge Clinic, via its financial sponsors Ares Private Equity Group, Guidon Partners and Athyrium Capital Management, expanding Physician-led Primary Care Services across Chicagoland Woodridge Clinic, founded in 1986, excels in primary care, diabetes management, and occupational therapy. Joining Duly gives its team access to new resources and technology, expanding specialty care and services in Lemont, Lombard, and Woodridge. This partnership strengthens coordinated, patient-focused care for local families and supports ongoing provider recruitment. (Link)

        10. Frontline Healthcare Partners acquires Integracare Inc. to drive expansion of Private-Pay Home Care across Ontario, Canada Integracare will benefit from expanded operational resources and Frontline’s healthcare investment expertise to reach new communities. The partnership preserves its focus on personalized, quality home care and workplace excellence, supporting growth beyond Toronto, Mississauga, and Ottawa. This move helps advance Integracare’s mission and expands personalized home health solutions across Ontario. (Link)

        11. Cerebral raises $25 Million in Latest Funding Round, Accelerating Growth and Platform Integration The capital infusion, following the Resilience Lab acquisition, will support Cerebral’s nationwide expansion, platform integration, and quality initiatives like improved clinical training. Funds will enhance telehealth services, solidify insurance partnerships, and drive innovation in therapy, psychiatry, and medication management, as the company rebuilds after leadership and regulatory challenges. (Link)

          12. Counsel Health raises $25 Million Series A Led by Andreessen Horowitz and GV to Launch Physician-Supervised AI Front Door for Healthcare Following $11 Million Seed Round Counsel Health’s platform delivers instant, context-aware medical guidance via chat or voice, using AI with physician oversight for diagnosis, prescriptions, or referrals and unlimited follow-up. It reports a 96% resolution rate, rapid response times, and measurable cost savings. Serving 100,000+ members now, it’s expanding to reach millions nationwide. (Link)

          13. Faeth Therapeutics raises $25 Million, led by S2G Investments, with Support from KdT Ventures, Khosla Ventures, Future Ventures, Cantos Ventures, Digitalis Ventures, B Capital Group, Avicella Capital, THO Seed Fund and Others Faeth Therapeutics’ funding will support a randomized phase 2 trial of its PIKTOR regimen after an 80% response rate and 11-month median progression-free survival in endometrial cancer. The capital enables insulin control research, expansion into rectal cancer and rare metabolic disorders, and growth of the MetabOS™ precision oncology platform. (Link)